Investigating Kidney Cancer Therapies
News Apr 13, 2016
The phase III study, co-authored by Timothy Kuzel, MD, ’87 ’90 GME, professor of Medicine in the Division of Hematology/Oncology and of Dermatology, tested the use of drugs sunitinib and sorafenib as options for adjuvant therapy – secondary treatment meant to stop cancer from coming back.
Both drugs have previously been shown to benefit patients with renal cell carcinoma when the disease has already spread to other parts of the body.
“This study was designed to determine if a one-year course of treatment with two different drugs that block blood vessel proliferation within the tumor microenvironment would improve the progression-free and overall survival of patients with renal cell cancer,” Dr. Kuzel said. “Unfortunately, neither of the drugs demonstrated benefit compared with the placebo control arm, and both study drugs were associated with significant side effects.”
Renal cell carcinoma, the most common type of kidney cancer, occurs when malignant cells develop from the lining of small tubes in the kidney responsible for filtering blood. About one-third of patients diagnosed with the cancer will die from metastatic disease. It is currently difficult to predict whether renal cell carcinoma will recur, which is why investigators are interested in discovering new adjuvant therapies.
The drugs sunitinib and sorafenib inhibit vascular endothelial growth factor, a protein involved in the formation of new blood vessels, a process thought to assist in tumor growth. The results of the trial, however, suggest that the development of blood vessels may not be associated with cancer recurrence after all – or that the benefits of inhibiting it are too small to have been detected in this trial.
In the study, nearly 2,000 patients randomly assigned to receive sunitinib, sorafenib or a placebo showed no significance differences in disease-free survival. More than half of the patients in the experimental groups experienced severe adverse events. Altogether, these results led the investigators to a clear conclusion.
“It’s important that practitioners do not use these drugs in patients with completely resected renal cell cancers that they feel are at high risk of recurrence,” said Dr. Kuzel, who is director of the Walter S. and Lucienne Driskill Immunotherapy Research Program within the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “This study reaffirms that observation and close surveillance should be recommended to assess risk of disease recurrence in this population, as per guidelines from the National Comprehensive Cancer Network.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019